Malaysia has registered the world’s first affordable – and effective – new drug for hepatitis C, offering the hope of accessible treatment to millions of people around the world at risk from a disease that has few early symptoms, is hard to diagnose, and is often seen as a “silent killer”. Al Jazeera reports that the drug, ravidasvir, was approved for use with an existing drug, sofosbuvir, in June, five years after the Malaysian government, partnered with the Drugs for Neglected Diseases initiative, a collaborative, non-profit drug research organisation to develop the drug. This month, Egypt, which has one of the highest incidences of hepatitis C in the world, also registered the drug and there are expectations that the combination therapy will secure approval in other countries in Southeast Asia and South America.